Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr-Jun;12(2):74-82.
doi: 10.4103/atm.ATM_231_16.

Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Affiliations
Review

Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Ibrahim Ahmed Janahi et al. Ann Thorac Med. 2017 Apr-Jun.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that often occurs in patients with asthma or cystic fibrosis (CF) and is characterized by a hypersensitivity response to the allergens of the fungus Aspergillus fumigatus. In patients with CF, growth of A. fumigatus hyphae within the bronchial lumen triggers an immunoglobulin E (IgE)-mediated hypersensitivity response that results in airway inflammation, bronchospasm, and bronchiectasis. In most published studies, the prevalence of ABPA is about 8.9% in patients with CF. Since the clinical features of this condition overlap significantly with that of CF, ABPA is challenging to diagnose and remains underdiagnosed in many patients. Diagnosis of ABPA in CF patients should be sought in those with evidence of clinical and radiologic deterioration that is not attributable to another etiology, a markedly elevated total serum IgE level (while off steroid therapy) and evidence of A. fumigatus sensitization. Management of ABPA involves the use of systemic steroids to reduce inflammation and modulate the immune response. In patients who do not respond to steroids or cannot tolerate them, antifungal agents should be used to reduce the burden of A. fumigatus allergens. Recent studies suggest that omalizumab may be an effective option to reduce the frequency of ABPA exacerbations in patients with CF. Further randomized controlled trials are needed to better establish the efficacy of omalizumab in managing patients with CF and ABPA.

Keywords: Allergic bronchopulmonary aspergillosis; allergic fungal mycosis; cystic fibrosis.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
A flow chart depicting the inclusion and exclusion of articles for the purpose of this review. ABPA = Allergic bronchopulmonary aspergillosis; MA = Meta-analyses; SR = Systematic reviews
Figure 2
Figure 2
A diagram depicting the model of pathogenesis of allergic bronchopulmonary aspergillosis. APC = Antigen-presenting cell; ECP = Eosinophil cationic protein; HLA = Human leukocyte antigen; IL = Interleukin; MBP = Major basic protein; NK = Natural killer

Similar articles

Cited by

References

    1. Strausbaugh SD, Davis PB. Cystic fibrosis: A review of epidemiology and pathobiology. Clin Chest Med. 2007;28:279–88. - PubMed
    1. Mornon JP, Lehn P, Callebaut I. Molecular models of the open and closed states of the whole human CFTR protein. Cell Mol Life Sci. 2009;66:3469–86. - PMC - PubMed
    1. Riordan JR. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol. 1993;55:609–30. - PubMed
    1. Sheppard MN, Nicholson AG. The pathology of cystic fibrosis. Curr Diagn Pathol. 2002;8:50–9.
    1. Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. Clin Chest Med. 2012;33:265–81. - PubMed